Newlink Genetics reported $100.65M in Cash and Equivalent for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Bristol Myers Squibb BMY:US $ 13540M 2516M
Capricor Therapeutics CAPR:US $ 40.84M 2.76M
Celldex Therapeutics CLDX:US $ 72.18M 28.74M
Eli Lilly And LLY:US $ 3788.2M 568.2M
Idera Pharmaceuticals IDRA:US $ 36.6M 3.99M
Intrexon XON:US $ 41.73M 5.32M
Nektar Therapeutics NKTR:US $ 54.02M 98.33M
Newlink Genetics NLNK:US $ 100.65M 7.05M
Prothena PRTA:US $ 600.1M 200.27M
Sarepta Therapeutics SRPT:US $ 1599.11M 98.16M
Vascular Biogenics VBLT:US 25.28M 6.38M
YTE INCY:US $ 1999.02M 201.44M